Toremifene plus androgen deprivation therapy (TOPADT) significantly improved biochemical recurrence in bone metastatic prostate cancer: A randomized controlled phase IIA trial

Category Primary study
JournalEuropean Urology, Supplements
Year 2016
This article has no abstract
Epistemonikos ID: bd02ccba8af28955306f393a0d955b49f603a8b5
First added on: Feb 07, 2025